Evidence map›Paper›PMID 26057452›Full record

ArticleBritish journal of cancer2015

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.

I Summerer, K Unger, H Braselmann, L Schuettrumpf, C Maihoefer, P Baumeister, T Kirchner, M Niyazi, E Sage, H M Specht and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. New evidence for miRNA testing in head and neck squamous cell cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Observational
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

I SummererResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
K Unger1] Research Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
H BraselmannResearch Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
L Schuettrumpf1] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Department of Radiation Oncology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany.
C Maihoefer1] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Department of Radiation Oncology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany.
P Baumeister1] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany.
T KirchnerInstitute of Pathology, Ludwig-Maximilians-Universitaet Muenchen, Thalkirchner Strasse 36, 80337 Munich, Germany.
M Niyazi1] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Department of Radiation Oncology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany.
E SageDepartment of Radiation Oncology, Technische Universitaet Muenchen, Ismaninger Strasse 22, 81675 Munich, Germany.
H M SpechtDepartment of Radiation Oncology, Technische Universitaet Muenchen, Ismaninger Strasse 22, 81675 Munich, Germany.
G Multhoff1] Department of Radiation Oncology, Technische Universitaet Muenchen, Ismaninger Strasse 22, 81675 Munich, Germany [2] Clinical Cooperation Group 'Innate Immunity', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
S MoertlInstitute of Radiation Biology, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
C Belka1] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Department of Radiation Oncology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany.
H Zitzelsberger1] Research Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany [2] Clinical Cooperation Group 'Personalized Radiotherapy of Head and Neck Cancer', Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany.
Helmholtz Zentrum München · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prediction of therapy response in head and neck squamous cell cancer (HNSCC) requires biomarkers, which are also a prerequisite for personalised therapy concepts. The current study aimed to identify therapy-responsive microRNAs (miRNAs) in the circulation that can serve as minimally invasive prognostic markers for HNSCC patients undergoing radiotherapy.

methodsWe screened plasma miRNAs in a discovery cohort of HNSCC patients before therapy and after treatment. We further compared the plasma miRNAs of the patients to age- and sex-matched healthy controls. All miRNAs identified as biomarker candidates were then confirmed in an independent validation cohort of HNSCC patients and tested for correlation with the clinical outcome.

resultsWe identified a signature of eight plasma miRNAs that differentiated significantly (P=0.003) between HNSCC patients and healthy donors. MiR-186-5p demonstrated the highest sensitivity and specificity to classify HNSCC patients and healthy individuals. All therapy-responsive and patient-specific miRNAs in plasma were also detectable in tumour tissues derived from the same patients. High expression of miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p in the plasma correlated with worse prognosis.

conclusionsCirculating miR-142-3p, miR-186-5p, miR-195-5p, miR-374b-5p and miR-574-3p represent the most promising markers for prognosis and therapy monitoring in the plasma of HNSCC patients. We found strong evidence that the circulating therapy-responsive miRNAs are tumour related and were able to validate them in an independent cohort of HNSCC patients.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCohort StudiesFemaleGene Expression ProfilingHead and Neck NeoplasmsHumansMaleMicroRNAsMiddle AgedPrognosisBiomarkers, TumorMicroRNAs

Identifiers

PMID26057452
PMCPMC4647540
OpenAlexW1488660005

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.